David Shaw
Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy
Grebely J, Feld J, Bruneau J, Daulouede J, Powis J, Bruggmann P, Matthews G, Kronborg I, Shaw D, Dunlop A, Hellard M, Applegate T, Crawford S, Dore G, Lacombe K, Dalgard O, Conway B, Cunningham E, Fraser C, Moriggia A, Gane E, Stedman C, Cooper C, Castro E, Schmid P, Petoumenos K, Hajarizadeh B, Marks P, Erratt A, D3FEAT Study Group. Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy. Int J Drug Policy 2018; 62:94-103.
29.10.2018Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy
29.10.2018Int J Drug Policy 2018; 62:94-103
Grebely Jason, Feld Jordan J, Bruneau Julie, Daulouede Jean-Pierre, Powis Jeff, Bruggmann Philip, Matthews Gail V, Kronborg Ian, Shaw David, Dunlop Adrian, Hellard Margaret, Applegate Tanya L, Crawford Sione, Dore Gregory J, Lacombe Karine, Dalgard Olav, Conway Brian, Cunningham Evan B, Fraser Chris, Moriggia Alberto, Gane Ed, Stedman Catherine, Cooper Curtis, Castro Erika, Schmid Patrick, Petoumenos Kathy, Hajarizadeh Behzad, Marks Phillipa, Erratt Amanda, D3FEAT Study Group
Enhancing patients' autonomy by involving them in research ethics committees.
Rakic M, Dittrich T, Elger B, Shaw D. Enhancing patients' autonomy by involving them in research ethics committees. Int J Qual Health Care 2017; 29:896-900.
01.11.2017Enhancing patients' autonomy by involving them in research ethics committees.
01.11.2017Int J Qual Health Care 2017; 29:896-900
Rakic Milenko, Dittrich Tolga, Elger Bernice S, Shaw David